Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease (Stages 4 and 5), Proteinuria
Conditions
Keywords
CKD, CHRONIC KIDNEY, KIDNEY DISEASE, KIDNEY DECLINE, PROGRESSION OF CKD
Brief summary
Outcome of use of a novel Modulator of Oxidative Phosphorylation on kidney function in patients with Chronic Kidney Disease
Detailed description
QRX-3 ( Eseronate ) is a formulated drug designed to supply and optimize NAD+ mitochondrial availability in order to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the NAD/NAD+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers . This novel drug therapy stabilized the intracellular oxidative phosphorylation process a pathway mechanism that is dysregulated or abnormal in the ongoing renal tubular cell injury and damage in chronic kidney disease. In this study the investigators evaluate the effect of intervention with this novel drug therapy on a chronic kidney disease CKD population with slowly progressively declining renal function.
Interventions
DRUGQRX-3
Compounded new drug regime
DRUGEseronate
Neukidney innovative drug
Sponsors
Neukidney Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with Chronic kidney disease * Estimated Glomerular function by MDRD of less than 60mls/min * Patients with declining renal function ( as measured by eGFR by MDRD ) * Rate of decline of eGFR over the last one year of less than 20% * Negative Serology markers for CKD etiology * Provider perceived adherence to study follow up
Exclusion criteria
* • Rapid rate of decline in kidney function of \> 20 % over last one year * Symptomatic renal failure * Presence of any suspected Acute renal failure superimposed * Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI * No known reversible cause of renal decline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decrease rate of GFR decline | 6 months | Comparism of percentage and mean change in GFR with time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect on proteinuria with time | 6 months | Rate of change in random urine protein/creatinine ratio |
Countries
United States
Outcome results
None listed